#ASCO22 – Estudo randomizado | Terapia tripla, transplante e manutenção até a progressão no mieloma.
13 Jun, 2022 | 14:37hTriplet Therapy, Transplantation, and Maintenance until Progression in Myeloma – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comunicado de imprensa: Improved progression-free survival in multiple myeloma patients following three-drug therapy with autologous stem cell transplant – Dana-Farber Cancer Institute
Comentário no Twitter
DETERMINATION: Among adults with multiple myeloma, continuous lenalidomide maintenance therapy after triplet therapy (RVD, plus ASCT) associated with longer PFS than triplet therapy alone. #ASCO22 https://t.co/YhKgjc1Enz pic.twitter.com/cU8nefokZo
— NEJM (@NEJM) June 5, 2022